News Headlines

  1. Sienna Biopharmaceuticals Announces Results From First-In-Human Study Of SNA-125 In Psoriasis And Continued Progression To Phase 2

    Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today announced results from a first-in-human study of its investigational new chemical entity SNA-125, a JAK3/TrkA inhibitor being evaluated as a first-in-class topically administered medication to treat mild-to-moderate psoriasis.

  2. Sharp Enters Validation Phase For New Clinical Packaging Facility In Wales

    Sharp – part of UDG Healthcare plc, a global leader in contract packaging and clinical supply services, has begun the validation phase of Sharp UK, a £9.5M Clinical Services Centre of Excellence in Rhymney, Wales.

  3. TrialKit, Native App For EDC And ePRO, To Be Available For Android Devices In September

    Fully-featured eClinical app, TrialKit, will soon be released on Google Play by Crucial Data Solutions, making clinical data collection and management possible on the majority of smartphones available today.

  4. TrialAssure Partners With Otsuka Pharmaceutical To Provide Clinical Trial Disclosure Reporting System For Global Pipeline

    TrialAssure – a leading, global company focused on developing clinical trial transparency tools – announced today that it will partner with Otsuka Pharmaceutical Development and Commercialization, Inc. (Otsuka) to implement its comprehensive transparency management system for all compounds in Otsuka’s drug development pipeline.

  5. CRF Health Launches Self-Service Model For TrialConsent® Platform

    CRF Health, the leading global provider of patient-centered eSource technology and service solutions for the life sciences industry, launches a self-service capability and a customer enablement program to empower CROs and Sponsors to manage all aspects of electronic informed consent using a licensed, cloud-based version of the industry’s first electronic informed consent platform with fully embedded design tool.

  6. Clementia Announces Completion Of Enrollment In Phase 3 MOVE Trial For FOP

    Clementia Pharmaceuticals Inc. (NASDAQ: CMTA), a clinical-stage company innovating treatments for individuals with ultra-rare bone disorders and other diseases, today announced the early completion of patient enrollment in the MOVE Trial, Clementia’s registrational Phase 3 clinical study evaluating the safety and efficacy of palovarotene for the treatment of patients with fibrodysplasia ossificans progressiva (FOP). A total of 99 patients were enrolled in the MOVE Trial at 15 sites in 11 countries worldwide.

  7. Altasciences To Acquire Preclinical Safety Testing Services

    Altasciences announced today that it has signed a definitive agreement to acquire the preclinical testing business of SNBL U.S.A. The transaction is expected to be completed at the end of September.

  8. Inovio Announces First Patient Dosed In Trial To Determine PENNVAX®-GP’s Ability To Induce Remission Of HIV Infection

    Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that the first participant has been dosed with PENNVAX®-GP in a randomized clinical trial that will evaluate its ability to drive remission of HIV infection. 

  9. TLC Doses First Patients In Phase I/II Trial Of TLC590 For Postsurgical Pain Management

    Taiwan Liposome Company, Ltd. (4152.TWO; “TLC”), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of medical needs in pain management, ophthalmology, and oncology, today announced the dosing of the first patients in a Phase I/II trial for TLC590. To date, the trial has enrolled 12 patients, 3 of whom were dosed on August 13, 2018.

  10. Gemphire Announces Termination Of Phase 2a Clinical Trial Of Gemcabene In Pediatric NAFLD

    Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), announces today that the Data and Safety Monitoring Board (DSMB) at Emory University School of Medicine overseeing the investigator-led open label Phase 2a proof-of-concept trial evaluating gemcabene in pediatric patients with non-alcoholic fatty liver disease (NAFLD) has recommended that the trial be terminated due to unanticipated problems.